BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31928970)

  • 1. The MBOAT7 rs641738 variant is associated with an improved outcome in primary sclerosing cholangitis.
    Freund C; Wahlers A; Begli NH; Leopold Y; Klöters-Plachky P; Mehrabi A; Mohr I; Sander J; Rupp C; Gotthardt DN; Weiss KH
    Clin Res Hepatol Gastroenterol; 2020 Oct; 44(5):646-652. PubMed ID: 31928970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Membrane-bound O-Acyltransferase7 rs641738 Variant in Pediatric Nonalcoholic Fatty Liver Disease.
    Di Sessa A; Umano GR; Cirillo G; Del Prete A; Iacomino R; Marzuillo P; Del Giudice EM
    J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):69-74. PubMed ID: 29601441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B.
    Thabet K; Chan HLY; Petta S; Mangia A; Berg T; Boonstra A; Brouwer WP; Abate ML; Wong VW; Nazmy M; Fischer J; Liddle C; George J; Eslam M
    Hepatology; 2017 Jun; 65(6):1840-1850. PubMed ID: 28109005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent.
    Mancina RM; Dongiovanni P; Petta S; Pingitore P; Meroni M; Rametta R; Borén J; Montalcini T; Pujia A; Wiklund O; Hindy G; Spagnuolo R; Motta BM; Pipitone RM; Craxì A; Fargion S; Nobili V; Käkelä P; Kärjä V; Männistö V; Pihlajamäki J; Reilly DF; Castro-Perez J; Kozlitina J; Valenti L; Romeo S
    Gastroenterology; 2016 May; 150(5):1219-1230.e6. PubMed ID: 26850495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between MBOAT7 rs641738 polymorphism and non-alcoholic fatty liver in overweight or obese children.
    Zusi C; Morandi A; Maguolo A; Corradi M; Costantini S; Mosca A; Crudele A; Mantovani A; Alisi A; Miraglia Del Giudice E; Targher G; Maffeis C
    Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1548-1555. PubMed ID: 33810963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children.
    Lin YC; Chang PF; Chang MH; Ni YH
    Liver Int; 2018 Jul; 38(7):1300-1307. PubMed ID: 29314568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.
    Donati B; Dongiovanni P; Romeo S; Meroni M; McCain M; Miele L; Petta S; Maier S; Rosso C; De Luca L; Vanni E; Grimaudo S; Romagnoli R; Colli F; Ferri F; Mancina RM; Iruzubieta P; Craxi A; Fracanzani AL; Grieco A; Corradini SG; Aghemo A; Colombo M; Soardo G; Bugianesi E; Reeves H; Anstee QM; Fargion S; Valenti L
    Sci Rep; 2017 Jul; 7(1):4492. PubMed ID: 28674415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MBOAT7 rs641738 variant in primary sclerosing cholangitis: A novel biomarker for prognostication.
    Rahal HK; Tabibian JH
    Clin Res Hepatol Gastroenterol; 2020 Oct; 44(5):619-621. PubMed ID: 31924553
    [No Abstract]   [Full Text] [Related]  

  • 9. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience.
    Goss JA; Shackleton CR; Farmer DG; Arnaout WS; Seu P; Markowitz JS; Martin P; Stribling RJ; Goldstein LI; Busuttil RW
    Ann Surg; 1997 May; 225(5):472-81; discussion 481-3. PubMed ID: 9193175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.
    Thabet K; Asimakopoulos A; Shojaei M; Romero-Gomez M; Mangia A; Irving WL; Berg T; Dore GJ; Grønbæk H; Sheridan D; Abate ML; Bugianesi E; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Spengler U; Nattermann J; Wahid A; Rojas A; White R; Douglas MW; McLeod D; Powell E; Liddle C; van der Poorten D; George J; Eslam M;
    Nat Commun; 2016 Sep; 7():12757. PubMed ID: 27630043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of hepatic Mboat7 leads to liver fibrosis.
    Thangapandi VR; Knittelfelder O; Brosch M; Patsenker E; Vvedenskaya O; Buch S; Hinz S; Hendricks A; Nati M; Herrmann A; Rekhade DR; Berg T; Matz-Soja M; Huse K; Klipp E; Pauling JK; Wodke JA; Miranda Ackerman J; Bonin MV; Aigner E; Datz C; von Schönfels W; Nehring S; Zeissig S; Röcken C; Dahl A; Chavakis T; Stickel F; Shevchenko A; Schafmayer C; Hampe J; Subramanian P
    Gut; 2021 May; 70(5):940-950. PubMed ID: 32591434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
    Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
    J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of MBOAT7 variant on hepatitis B and C infections in Moroccan patients.
    Ezzikouri S; Elfihry R; Chihab H; Elmessaoudi-Idrissi M; Zaidane I; Jadid FZ; Karami A; Tahiri M; Elhabazi A; Kabine M; Chair M; Pineau P; Benjelloun S
    Sci Rep; 2018 Aug; 8(1):12247. PubMed ID: 30116012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of the association between MBOAT7 rs641738, TM6SF2 rs58542926 and nonalcoholic fatty liver disease susceptibility.
    Xia Y; Huang CX; Li GY; Chen KH; Han L; Tang L; Luo HQ; Bao MH
    Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):533-541. PubMed ID: 30824369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A frequent PNPLA3 variant is a sex specific disease modifier in PSC patients with bile duct stenosis.
    Friedrich K; Rupp C; Hov JR; Steinebrunner N; Weiss KH; Stiehl A; Brune M; Schaefer PK; Schemmer P; Sauer P; Schirmacher P; Runz H; Karlsen TH; Stremmel W; Gotthardt DN
    PLoS One; 2013; 8(3):e58734. PubMed ID: 23505555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study.
    de Vries EMG; Färkkilä M; Milkiewicz P; Hov JR; Eksteen B; Thorburn D; Chazouillères O; Pares A; Nygård S; Gilja OH; Wunsch E; Invernizzi P; Carbone M; Bernuzzi F; Boberg KM; Røsjø H; Rosenberg W; Beuers UH; Ponsioen CY; Karlsen TH; Vesterhus M
    Liver Int; 2017 Oct; 37(10):1554-1561. PubMed ID: 28267887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MBOAT7 rs641738 Variant Is Not Associated with an Increased Risk of Hepatocellular Carcinoma in a Latin American Cohort.
    Goble S; Akambase J; Prieto J; Balderramo D; Ferrer JD; Mattos AZ; Arrese M; Carrera E; Groothuismink ZMA; Oliveira J; Boonstra A; Debes JD
    Dig Dis Sci; 2023 Nov; 68(11):4212-4220. PubMed ID: 37684433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TLR4, TLR9, and NLRP3 in biliary epithelial cells of primary sclerosing cholangitis: relationship with clinical characteristics.
    Matsushita H; Miyake Y; Takaki A; Yasunaka T; Koike K; Ikeda F; Shiraha H; Nouso K; Yamamoto K
    J Gastroenterol Hepatol; 2015 Mar; 30(3):600-8. PubMed ID: 25160604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum miRNA-122 is an independent biomarker of survival in patients with primary sclerosing cholangitis.
    Friedrich K; Baumann C; Wannhoff A; Rupp C; Mehrabi A; Weiss KH; Gotthardt DN
    J Gastrointestin Liver Dis; 2018 Jun; 27(2):145-150. PubMed ID: 29922759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.
    Gordon FD; Goldberg DS; Goodrich NP; Lok AS; Verna EC; Selzner N; Stravitz RT; Merion RM
    Liver Transpl; 2016 Sep; 22(9):1214-22. PubMed ID: 27339253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.